Atossa Therapeutics (ATOS) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 08, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'ATOSSA GENETICS INC	'
Entity Central Index Key	'0001488039	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'ATOS	'
Entity Common Stock, Shares Outstanding	'	18,024,824
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Assets	'	'
Cash and cash equivalents	$7,693,561	$1,725,197
Accounts receivable, net	299,338	141,665
Prepaid expense	559,386	122,633
Retainers (deposits)	43,160	0
Total Current Assets	8,595,445	1,989,495
Fixed Assets	'	'
Furniture and equipment, net	443,272	159,967
Total Fixed Assets	443,272	159,967
Other Assets	'	'
Security deposit	36,446	36,447
Intangible assets, net	4,407,058	4,640,224
Total Other Assets	4,443,504	4,676,671
Total Assets	13,482,221	6,826,133
Liabilities and Stockholders' Equity	'	'
Accounts payable	31,131	68,217
Accrued expenses	1,069,759	1,374,385
Deferred rent	60,753	0
Payroll liabilities	357,489	207,996
Contingent liabilities	402,840	0
Other current liabilities	20,300	0
Total Current Liabilities	1,942,272	1,650,598
Stockholders' Equity	'	'
Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding	0	0
Common stock - $.001 par value; 75,000,000 shares authorized, 17,444,824 and 12,919,367 shares issued and outstanding	17,445	12,919
Additional paid-in capital	29,281,396	14,894,522
Accumulated deficit	-17,758,892	-9,731,906
Total Stockholders' Equity	11,539,949	5,175,535
Total Liabilities and Stockholders' Equity	$13,482,221	$6,826,133

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized	75,000,000	75,000,000
Common stock, shares issued	17,444,824	12,919,367
Common stock, shares outstanding	17,444,824	12,919,367

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		53 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenue	'	'	'	'	'
Diagnostic testing service	$72,187	$104,011	$361,905	$376,696	$837,307
Product sales	4,410	1,565	223,440	6,690	231,380
Total Revenue	76,597	105,576	585,345	383,386	1,068,687
Cost of Revenue	'	'	'	'	'
Diagnostic testing service	25,938	9,000	75,893	29,985	111,638
Product sales	0	0	238,669	0	243,833
Total Cost of Revenue	25,938	9,000	314,562	29,985	355,471
Loss on reduction of inventory to LCM	0	6,077	0	29,884	121,910
Gross Profit	50,659	90,499	270,783	323,517	591,306
Selling expenses	373,418	87,704	965,383	281,971	1,605,259
Research and development expenses	321,111	548,108	731,258	1,508,944	4,288,644
General and administrative expenses	2,858,027	590,359	6,600,819	1,896,254	12,423,155
Total operating expenses	3,552,556	1,226,171	8,297,460	3,687,169	18,317,058
Operating Loss	-3,501,897	-1,135,672	-8,026,677	-3,363,652	-17,725,752
Interest income	53	46	53	1,219	6,641
Interest expense	1	7,756	360	11,816	39,531
Net Loss before Income Taxes	-3,501,845	-1,143,382	-8,026,984	-3,374,249	-17,758,642
Income Taxes	0	0	0	0	250
Net Loss	($3,501,845)	($1,143,382)	($8,026,984)	($3,374,249)	($17,758,892)
Loss per common share - basic and diluted (in dollars per share)	($0.22)	($0.10)	($0.55)	($0.30)	($1.95)
Weighted average shares outstanding, basic & diluted (in shares)	15,830,033	11,256,867	14,697,221	11,256,867	9,127,656

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		53 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Net loss	($8,026,984)	($3,374,249)	($17,758,892)
Common shares issued for services	144,391	0	215,392
Compensation cost for stock options granted	1,187,717	96,251	1,479,981
Loss on reduction of inventory to LCM	0	29,884	121,910
Loan initiation fee accrued for notes payable	0	0	2,000
Depreciation and amortization	350,536	25,586	496,711
Contingent loss	402,840	0	402,840
Bad debt expense	228,841	0	228,841
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'	'
Increase in accounts receivable	-386,514	-174,183	-528,179
Increase in inventory	0	-29,884	-121,910
Decrease (Increase) in prepaid expenses	71,439	-8,791	-51,194
Increase in security deposits	-43,160	-30,589	-79,608
Decrease (Increase) in accounts payable	-37,086	7,335	31,131
Decrease in accrued payroll	149,493	0	149,493
Increase in deferred rent	60,753	0	60,753
Decrease (Increase) in accrued expenses	-304,626	1,491,014	1,322,756
Increase in other current liabilities	20,300	0	20,300
Net cash used in operating activities	-6,182,060	-1,967,626	-14,007,675
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of furniture & fixtures	-346,007	0	-537,054
Purchase of software	-54,667	0	-135,133
Net cash used in investing activities	-400,674	0	-672,187
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Net proceeds from issuance of common stocks and warrants	12,551,098	400,000	22,375,423
Repayments of bank line of credit	0	-750,000	0
Proceeds from (repayments of) loans from related parties	0	75,375	-2,000
Cash released from commercial line of credit	0	750,000	0
Net cash provided by financing activities	12,551,098	475,375	22,373,423
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS	5,968,364	-1,492,251	7,693,561
CASH & CASH EQUIVALENTS, BEGINNING BALANCE	1,725,197	1,910,821	0
CASH & CASH EQUIVALENTS, ENDING BALANCE	7,693,561	418,570	7,693,561
SUPPLEMENTAL DISCLOSURES:	'	'	'
Interest paid	359	13,892	33,067
Income taxes paid	0	0	250
NONCASH INVESTING AND FINANCING ACTIVITIES:	'	'	'
Common stock and warrants issued for asset purchase	0	4,674,853	4,674,853
Options issued for previously accrued director compensation	0	45,000	45,000
Commitment shares distributed for capital contribution	2,387,250	0	2,387,250
Amortization of commitment shares issued for distributed shares	$1,879,058	$0	$1,879,058

NATURE_OF_OPERATIONS

NATURE OF OPERATIONS	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	NOTE 1: NATURE OF OPERATIONS
	The Company’s operations began in December 2008 with the negotiations for the acquisition of the Mammary Aspirate Specimen Cytology Test System, or the MASCT System, patent rights and assignments and the FDA clearances for marketing, which acquisition was completed in January 2009. Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market the MASCT System, which was cleared by the FDA in 2003 as a medical device that is intended for use in the collection of nipple aspirate fluid for laboratory cytological testing.  The Company’s fiscal year ends on December 31st.
	In December 2011, the Company established the National Reference Laboratory for Breast Health, or NRLBH, as a wholly-owned subsidiary. NRLBH is the Company’s CLIA-certified laboratory where the ForeCYTE and ArgusCYTE test specimens are examined by cytopathology.
	In September 2012, the Company acquired the assets of Acueity Healthcare, Inc. (“Acueity”). The purchased assets included 35 issued patents (18 issued in the U.S. and 17 issued in foreign countries) and 41 patent applications (32 in the U.S. and 9 in foreign countries), six 510(k) FDA marketing authorizations related to the manufacturing, use, and sale of the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $400,000. The microendoscopes are less than 0.9 mm outside diameter and can be inserted into a milk duct. This permits a physician to pass a microendoscope into the milk duct system of the breast and view the duct system via fiberoptic video images. Abnormalities that are visualized can then be biopsied from inside the duct with the biopsy tools that are inserted adjacent to the microendoscope. The patents relate to intraductal diagnostic and therapeutic devices and methods of use. The Company did not, however, acquire an inventory of these diagnostic tools, manufacturing capabilities or any personnel to market and sell the tools. The Company cannot provide any assurance that it will be successful commercializing these tools.
	On October 4, 2013 the Company commenced the voluntary recall of the ForeCYTE Breast Health Test (also known as the MASCT System or ForeCYTE Test).  As a result of this recall, this product is currently not being marketed or distributed in the U.S.  The Company intends to obtain an additional FDA 510(k) clearance from the FDA for the ForeCYTE Test and to re-launch the test upon receiving regulatory clearance.
	Development Stage Risk
	From April 30, 2009 (inception) through September 30, 2013, the Company earned $1,068,687 in revenue from the sale of its products and laboratory services. The Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”, which was previously Statement of Financial Accounting Standards No. 7 (“SFAS 7”). Among the disclosures required by ASC 915 are that the Company’s financial statements be identified as those of a development stage company, and that the statements of operations, stockholders’ equity and cash flows disclose activity since the date of the Company’s inception.
	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plan will be successfully executed. The Company’s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.

GOING_CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2013
Going Concern Disclosure [Abstract]	'
Going Concern Disclosure [Text Block]	'
	NOTE 2: GOING CONCERN
	The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Management’s Plan to Continue as a Going Concern
	In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plans to obtain such resources for the Company include (1) obtaining capital from the sale of its equity securities, (2) sales of the ForeCYTE System and laboratory service revenue (once cleared by the FDA and re-launched), and (3) short-term or long-term borrowings from banks, stockholders or other party(ies) when needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.
	The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually to secure other sources of financing and attain profitable operations.

SUMMARY_OF_ACCOUNTING_POLICIES

SUMMARY OF ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 3: SUMMARY OF ACCOUNTING POLICIES
	Basis of Presentation:
	The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiary NRLBH. All significant intercompany account balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.
	Recently Issued Accounting Pronouncements:
	The Company has adopted all recently issued accounting pronouncements that management believes to be applicable to the Company. The adoption of these accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.
	Revenue Recognition:
	Overview
	The Company recognizes product and service revenue in accordance with GAAP when the following overall fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or the service has been performed, (iii) the Company’s price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured.
	Product Revenue
	The Company recognizes revenue for sales of the MASCT kits and devices on an accrual basis for sales to distributors when the above four criteria are met. For sales of MASCT kits and devices directly to physicians, the revenue is typically recognized upon receipt of cash as the Company has an insufficient sales history on which to determine the collectability. Shipping documents and the completion of any customer acceptance requirements, when applicable, will be used to verify product delivery. The Company will assess whether a price is fixed or determinable based upon the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. For sales directly to physicians, once a history of sales and collectability has been established, the Company will recognize revenue on an accrual basis with an offsetting reserve for doubtful accounts based on the history during the initial sales period.
	Service Revenue
	The Company records revenue for diagnostic testing on an accrual basis at the Medicare allowed and invoiced amount. Amounts invoiced above the Medicare amount, namely non-Medicare, are not recognized on an accrual basis and instead are recognized on a cash basis as received. Diagnostic testing revenue at the Medicare rate is recognized upon completion of the test, communication of results to the patient’s physician, and when collectability is reasonably assured. Customer purchase orders and/or contracts will generally be used to determine the existence of an arrangement. Once the Company has historical sales and can determine the proper amount to recognize as uncollectible, it will then begin to recognize the entire amount, both Medicare and non-Medicare billing on an accrual basis, with an offsetting allowance for doubtful accounts recorded based on history. The Company estimates it will utilize the diagnostic testing revenue history to determine a proper allowance for doubtful accounts beginning in 2014.
	Cash and Cash Equivalents:
	Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.
	Use of Estimates:
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
	Accounts Receivable:
	Accounts receivable are recorded at net realizable value consisting of the carrying amount less allowance for doubtful accounts, as needed. The Company assesses the collectability of accounts receivable based primarily upon the creditworthiness of the customer as determined by credit checks and analysis, as well as the customer’s payment history. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company’s allowance for doubtful accounts and bad debt expenses as of September 30, 2013 and December 31, 2012 was $228,841 and $0, respectively.
	Inventories:
	The Company’s inventories are stated at lower of cost or market. Cost is determined on a moving-average basis. Costs of inventories include purchase and related costs incurred in delivering the products to their present location and condition. Market value is determined by reference to selling prices after the balance sheet date or to management’s estimates based on prevailing market conditions. Inherent in the lower of cost or market calculation are several significant judgments based on a review of the aging of the inventory, inventory movement of products, economic conditions, and replacement costs. Because the sales price of the MASCT System was substantially lower than its cost for the period ended September 30, 2013 and December 31, 2012, resulting in the net realizable value of the MASCT System being determined at zero as of September 30, 2013 and December 31, 2012, through taking the average sales price subtracted by selling expenses per unit. The Company assessed and recorded $0 and $29,884 loss on reduction of inventory to the lower of cost or market for the nine months ended September 30, 2013 and for the year ended December 31, 2012, respectively. Additionally, management periodically evaluates the composition of its inventories at least quarterly to identify slow-moving and obsolete inventories to determine if any valuation allowance is required. As of September 30, 2013 and December 31, 2012, management had identified no slow moving or obsolete inventory. The Company outsources product manufacturing to outside manufacturer contactors.  The ownership of the goods transfers from the manufacturer to the Company’s customer at the time the products are shipped to the customers. As of September 30, 2013, there are no inventories on our books.
	The Company provides, either directly or through distributors, the ForeCYTE testing specimen collection kits to doctors with our MASCT System for doctors to collect specimens that are returned to the NRLBH for diagnostic analysis. These collection kits are considered part of the MASCT System. The Company’s direct sales personnel distributes the kits directly to physicians free of charge, or by offering a rebate to physicians. The Company has not intended to deem the kits as a primary product line due to their nominal cost and value per unit. As a result, the kits are immediately expensed and recorded as selling expense upon purchasing of the kits.
	Property, plant, and equipment:
	Property, plant and equipment are stated at cost less accumulated depreciation.  Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized.  When property, plant and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.
	Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Machinery and equipment		5
	Leasehold improvements		2.083
	Intangible assets:
	Intangible assets consist of intellectual property and software acquired in the Acueity asset purchase. At least annually, we evaluate purchased intangibles for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense. There was no impairment of intangible assets as of and for the nine months ended September 30, 2013 and year ended December 31, 2012, respectively.
	Amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Patents		14-Sep
	Software		3
	Research and Development Expenses:
	Research and development costs are generally expensed as incurred. The Company’s research and development expenses consist of costs incurred for internal and external research and development.
	Share-Based Payments:
	In December 2004, the Financial Accounting Standards Board, or the FASB, issued the Statement of Financial Accounting Standards, or SFAS, No. 123(R), “Share-Based Payment”, which replaces SFAS No. 123 and supersedes APB Opinion No. 25. SFAS No. 123(R) is now included in the FASB’s ASC Topic 718, “Compensation – Stock Compensation.” Under SFAS No. 123(R), companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees or independent contractors are required to provide services. Share-based compensation arrangements include stock options and warrants, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. In March 2005, the SEC issued Staff Accounting Bulletin No. 107, or SAB 107, which expresses views of the staff regarding the interaction between SFAS No. 123(R) and certain SEC rules and regulations and provides the staff’s views regarding the valuation of share-based payment arrangements for public companies. SFAS No. 123(R) permits public companies to adopt its requirements using one of two methods. On April 14, 2005, the SEC adopted a new rule amending the compliance dates for SFAS No. 123(R). Companies may elect to apply this statement either prospectively, or on a modified version of retrospective application under which financial statements for prior periods are adjusted on a basis consistent with the pro forma disclosures required for those periods under SFAS No. 123.
	The Company has fully adopted the provisions of FASB ASC 718 and related interpretations as provided by SAB 107. As such, compensation cost is measured on the date of grant as the fair value of the share-based payments. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

PREPAID_EXPENSES

PREPAID EXPENSES	9 Months Ended
	Sep. 30, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Prepaid Expenses [Text Block]	'
	NOTE 4: PREPAID EXPENSES
	Prepaid expenses consisted of the following:
		September 30,		December 31,
		2013		2012
	Prepaid stock purchase agreement service fee	$	508,442	$	-
	Prepaid insurance		27,445		62,551
	Prepaid hardware/software maintenance and support service fee		23,499		20,000
	Prepaid payroll taxes		-		40,082
		$	559,386	$	122,633

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT, AND EQUIPMENT	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	NOTE 5: PROPERTY, PLANT, AND EQUIPMENT
	Property, plant and equipment consisted of the following:
		September 30,		December 31,
		2013		2012
	Machinery and equipment	$	269,771	$	97,383
	Leasehold improvements		93,665		93,665
	Capitalized new product development costs		173,766		-
	Less: Accumulated depreciation		-93,930		-31,081
	Property, plant, and equipment, net	$	443,272	$	159,967
	Depreciation expense for the nine months ended September 30, 2013 and 2012 was $62,849 and $12,970, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	NOTE 6: INTANGIBLE ASSETS
	Intangible assets consisted of the following:
		September 30,		December 31,
		2013		2012
	Patents	$	4,704,853	$	4,704,853
	Software		105,133		50,466
	Less: Accumulated amortization		-402,928		-115,095
		$	4,407,058	$	4,640,224
	Intangible assets amounted to $4,407,058 and $4,640,224 as of September 30, 2013 and December 31, 2012, respectively, and consisted of patents and software acquired. The acquired software mainly consisted of $58,000 in laboratory software and $31,500 in the newly developed Company website.  The amortization period for the purchased software is 3 years. Amortization expense related to software for the nine months ended September 30, 2013 and 2012 was $15,322 and $12,616, respectively.
	Patents amounted to $4,704,853 and $4,704,853 as of September 30, 2013 and December 31, 2012, respectively, and mainly consisted of patents acquired from Acueity on September 30, 2012 in an asset purchase transaction (see Note 13). Patent assets are amortized based on their determined useful life, and tested annually for impairment. The amortization period was from 9 to 14 years. Amortization expense related to patents was $272,511 and $0 for the nine months ended September 30, 2013 and 2012, respectively.
	Future estimated amortization expenses as of September 30, 2013 for the five succeeding years is as follows:
	As of September 30,	Amounts
	2014	$	393,073
	2015		381,331
	2016		378,781
	2017		363,902
	2018		363,028
	Thereafter		2,526,943
		$	4,407,058

PAYROLL_LIABILITIES

PAYROLL LIABILITIES	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	NOTE 7: PAYROLL LIABILITIES:
	Payroll liabilities consisted of the following:
		September 30,		December 31,
		2013		2012
	Accrued bonus payable	$	297,290	$	189,131
	Accrued payroll liabilities		40,318		-
	Accrued payroll tax liabilities		19,881		18,865
		$	357,489	$	207,996

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2013

Stockholders' Equity Note [Abstract]

'

Stockholders' Equity Note Disclosure [Text Block]

'

NOTE 8: STOCKHOLDERS’ EQUITY

The Company is authorized to issue a total of 85,000,000 shares of stock consisting of 75,000,000 shares of Common Stock, par value $0.001 per share, and 10,000,000 shares of Preferred Stock, par value $0.001 per share.

Reverse Stock-Split

On September 28, 2010, the Board of Directors approved a 1-for-2.26332 reverse share split for all issued and outstanding shares of Common Stock, with no change to the par value of the Common Stock.

Prior Issuances of Common Stock at Inception

On April 30, 2009 (inception), the Company issued 1,767,316 shares (or 4,000,000 shares prior to the reverse stock-split on September 28, 2010) to Ensisheim Partners LLC, a related party to the Company through common ownership, for cash in the amount of $24,000, or $0.014 per share (or $0.006 per share prior to the reverse stock-split on September 28, 2010); 1,325,487 shares (or 3,000,000 shares prior to the reverse stock-split on September 28, 2010) to Manistee Ventures LLC, a related party to the Company through common ownership, for cash in the amount of $18,000, or $0.014 per share (or $0.006 per share prior to the reverse stock-split on September 28, 2010); and 883,662 shares (or 2,000,000 shares prior to the reverse stock-split on September 28, 2010) to the Chairman, CEO and President of the Company at that time for cash in the amount of $12,000, or $0.014 per share (or $0.006 per share prior to the reverse stock-split on September 28, 2010).

Private Placements and Warrants

On April 28, May 31, June 10, and June 23, 2011, pursuant to Securities Purchase Agreements with various investors (the “Investors”), the Company issued 5,256,800 shares of the Company’s common stock and 5,256,800 warrants (the “Investor Warrants”), each of which entitles the investors to purchase the Company’s common stock, exercisable for 1.60 per share, for aggregate gross proceeds of $6,571,000 (the “Private Placement”).

Placement Agent Fees

In connection with the Private Placement, the Company paid Dawson James Securities, Inc. (the “Placement Agent”), a cash fee equal to 10% of the gross proceeds from sale of the common stocks and warrants, plus a 3% non-accountable expense allowance, which resulted in a payment to the Placement Agent of an aggregate of $857,230 (the “Placement Agent Fee”). In addition, the Company entered into Warrant Agreements with the Placement Agent pursuant to which the Placement Agent received 788,520 warrants, each of which entitles the Placement Agent to purchase one share of the Company’s common stock at $1.60 per share, plus an additional 788,520 warrants (collectively with the warrants exercisable at $1.25 per share, the “Placement Agent Warrants”), each of which entitles the placement agent to purchase the Company’s common stock at $1.25 per share. The cash payment of the $857,230 Placement Agent Fee and the $495,876 aggregated initial fair value of the Placement Agent Warrants (see Fair Value Considerations below) were directly attributable to an actual offering and were charged through additional paid-in capital in accordance with the SEC Staff Accounting Bulletin (SAB) Topic 5A.

Warrants

The Warrants, including the Investor Warrants and the Placement Agent Warrants, are exercisable at any time commencing after June 23, 2011 which is the date that the Company completed a “significant private financing” under the terms of the Warrants (the “Initial Exercise Date”). The Warrants shall expire and no longer be exercisable on the fifth anniversary of the Initial Exercise Date (the “Expiration Date”). The Warrants may be exercised for cash or, at the option of the holder, may be exercised on a cashless basis; however if a registration statement is in effect for the resale of the common stock issuable upon exercise of the Warrants then the Warrants cannot be exercised on a cashless basis. As of September 30, 2013 such a registration statement was in effect and, therefore, the Warrants cannot be exercised on a cashless basis.

As of September 30, 2013, 4,775,550 warrants are outstanding including 325,000 warrants issued in the Acueity transation described below and substantially all of the Placement Agents Warrants have been exercised. There are no redemption features embodied in the Warrants and they have met the conditions provided in current accounting standards for equity classification.

Fair Value Considerations

The Company’s accounting for the issuance of warrants to the Investors and the Placement Agent required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The warrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments.

The Investor Warrants and the Placement Agent Warrants were initially valued at $1,808,025 or $0.344 per warrant, $228,712 or $0.290 per warrant, and $267,164 or $0.339 per warrant, respectively. The following tables reflect assumptions used to determine the fair value of the Warrants:

Fair

April-June2011

December 2011

Value

Investor Warrants

Placement Agent

Placement

Hierarchy

Warrants

Agent

Level

Warrants

Indexed shares

5,256,800

788,520

788,520

Exercise price

$

1.6

$

1.6

$

1.25

Significant assumptions:

Stock price

3

$

0.906

$

0.906

$

0.906

Remaining term

3

6 years

6 years

6 years

Risk free rate

2

2.49

%

1.12

%

1.12

%

Expected volatility

3

53.55

%

54.21

%

54.21

%

Fair value hierarchy of the above assumptions can be categorized as follows:

-1

There were no Level 1 inputs.

-2

Level 2 inputs include:

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

-3

Level 3 inputs include:

Stock price- The Company’s common stock was not publicly traded at the time the Warrants were issued. Therefore, the stock price was determined implicitly from an iterative process in order for the combined fair value of the common stock and the warrants to equal the amount of proceeds received in the Private Placement, based upon the assumption that the Private Placement was the result of an arm’s length transaction.

Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.

Asset Purchase and Warrants

On September 30, 2012, pursuant to the asset purchase agreement with Acueity, the Company issued 862,500 shares of common stock and 325,000 warrants (“Acueity Warrants”) to the shareholders of Acueity, each of which entitles the recipients to subscribe for and purchase from the Company one share of the Company’s common stock at $5.00 per share (the “Exercise Price”), subject to a six-month lock up agreement.

Warrants

The Acueity Warrants are exercisable at any time commencing after September 30, 2012 (the “Issuance Date”) and shall expire and no longer be exercisable on the fifth anniversary of the Issuance Date (the “Expiration Date”). The Company may at any time during the term of the Acueity Warrants reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company. The Acueity Warrants do not have a cashless exercise provision. There are no redemption features embodied in the Acueity Warrants and they have met the conditions provided in current accounting standards for equity classification.

Fair Value Considerations

The Company’s accounting for the issuance of the Acueity Warrants required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The warrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments.

The Acueity Warrants were valued at $762,353 or $2.3457 per warrant. The following tables reflect assumptions used to determine the fair value of the Warrants:

Fair

September 2012

Value

Hierarchy

Level

Acueity Warrants

Indexed shares

325,000

Exercise price

$

5

Significant assumptions:

Stock price

3

$

5

Remaining term

3

5 years

Risk free rate

2

0.62

%

Expected volatility

3

56.54

%

Fair value hierarchy of the above assumptions can be categorized as follows:

-1

There were no Level 1 inputs.

-2

Level 2 inputs include:

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

-3

Level 3 inputs include:

Stock price- The Company’s common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).

Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.

As of September 30, 2013, the Company has granted warrants to purchase 58,500 shares of common stock to the placement agent in connection with the financing facility with Aspire Capital. The warrants are exercisable at $5.80 or $5.70 per share and expire in 2017. An expense of $72,549 has been recognized during 2013 for issuance of these warrants.

On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan, or the 2010 Plan, subject to stockholder approval, to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stockholder approval. An aggregate of 1,000,000 shares (or 2,263,320 shares prior to the reverse stock-split on September 28, 2010) were initially reserved for issuance in connection with awards granted under the 2010 Plan, such number of shares to be subject to adjustment as provided in the plan and in any award agreements entered into by the Company under the plan, and upon the exercise or conversion of any awards granted under the plan. On January 1, 2012, 450,275 shares were added to the 2010 Plan and on January 1, 2013, 500,000 shares were added to the 2010 Plan, as provided under the terms of the 2010 Plan.

The Company granted options to purchase 122,740 and 857,394 shares of common stock to employees during the three months and nine months ended September 30, 2013, respectively.  The Company issued zero and 5,546 shares of common stocks in connection with the exercise of employee’s stock options during the three months and nine months ended September 30, 2013.  As of September 30, 2013, there are 471,624 options available for grant under the 2010 Plan.

INCOME_TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 9: INCOME TAXES
	The Company accounts for income taxes as outlined in ASC 740, “Income Taxes”, which was previously Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes” (“SFAS 109”). Under the asset and liability method of SFAS 109, deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
	As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of September 30, 2013 and December 31, 2012 due to the Company’s continuing operating losses.

CONCENTRATION_OF_CREDIT_RISK

CONCENTRATION OF CREDIT RISK	9 Months Ended
	Sep. 30, 2013
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	NOTE 10: CONCENTRATION OF CREDIT RISK
	Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At September 30, 2013 and December 31, 2012, the Company had $7,443,561 and $1,475,197 in excess of the FDIC insured limit, respectively.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE 11: COMMITMENTS AND CONTINGENCIES
	Lease Commitments
	On September 29, 2010, the Company entered into a commercial lease agreement with CompleGen, Inc. for laboratory space located in Seattle, WA. The lease provides for monthly rent of $3,658 and a security deposit of $3,658. The lease terms are from September 29, 2010 through March 31, 2011, at which time the lease has converted to month to month unless two months’ prior written notice of the intent to terminate the agreement is given. The monthly rent for the lease increased to $4,267 commencing January 2012. For the year ended December 31, 2012, the Company incurred $46,529 of rent expense for the lease. The lease was terminated in December 2012, and the rental deposit was applied to the rent of the final month.
	On March 4, 2011, the Company entered into a commercial lease agreement with Sanders Properties, LLC for office space located in Seattle, WA. The lease provides for monthly rent of $1,100 and a security deposit of $1,500. The lease terms are from April 1, 2011 through March 31, 2014. For the nine months ended September 30, 2013, the Company incurred $8,800 of rent expense for the lease.
	On December 9, 2011, the Company entered into another commercial lease agreement with Fred Hutchinson Research Center for lab and office space located in Seattle, WA. The lease provides for monthly rent of $16,395 for the period from February 24, 2012 to August 31, 2012, $19,923 for the period from September 1, 2012 to August 31, 2013, and $20,548 for the period from September 1, 2013 to November 29, 2014. The security deposit of $32,789 was paid in March 2012 and recorded as Security Deposit on the consolidated balance sheet as of December 31, 2012. For the nine months ended September 30, 2013, the Company incurred $233,260 of rent expense for the lease, which included leasing office management expenses.
	In July 2013, the Company entered into an agreement with ARE LLC (Alexandria) to lease additional office spaces in our existing building under a separate lease agreement. The lease is from August 2013 through November 2014, and the gross rent is $ 4,800 per month.
	The future minimum lease payments due subsequent to September 30, 2013 under all non-cancelable operating leases for the next five years are as follows:
	As of September 30,	Amount
	2014	$	380,767
	2015		62,451
	2016		-
	2017		-
	2018		-
	Thereafter		-
	Total minimum lease payments	$	443,218
	Affymetrix Purchase Commitment
	In September 2013, the Company entered into an “Ownership Program Agreement” with Affymetrix, Inc, a manufacturer of GeneChip Systems, where Affymetrix has agreed to loan a GeneChip System 3000Dx v.2 (“instrument”) to us if we purchase and take delivery of a minimum thirty GeneChip Human Genme U133 Plus 2.0 (30-pack) arrays at $21,590 per 30 pack for the next three years for a total purchase obligation of $647,700 with a minimum purchase of ten 30-pack arrays per contract year.  At the end of the three year contract, upon fulfillment of the purchase commitment, the instrument title and ownership transfer to Atossa at no additional cost.   In addition to the GeneChip Human Genme, we must purchase a two year service contract for $51,600 to cover maintenance of the instrument during the contract period.   We placed an initial order for four 30-pack arrays in September 2013 for $94,723.  We are obligated to purchase 26 additional arrays during the next three year contract term.
	Contingencies
	On June 30, 2011, Robert Kelly, the Company’s former President, filed a counterclaim against the Company in an arbitration proceeding, alleging breach of contract in connection with the termination of a consulting agreement between Mr. Kelly (dba Pitslayer LLC) and the Company that was entered into in July 2010 in connection with his resignation from the Company as President and a director. The consulting agreement was terminated by the Company in September 2010. Mr. Kelly seeks $450,000 in compensatory damages, which is the amount he claims would have been earned had the consulting agreement been fulfilled to completion.
	On December 11, 2012, Mr. Kelly filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the termination of Mr. Kelly’s consulting contract and the rescission of shares issued to him in July 2010 in connection with his resignation from the Company as President and a director.  The specific amount of damages sought is to be proven at trial and is not specified. On July 8, 2013, the court granted the Company’s motion to compel arbitration of these claims and therefore this action was dismissed.
	On February 26, 2013, Mr. Victor Cononi filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the rescission of shares issued to him in July 2010 in connection with Mr. Kelly’s resignation from the Company as President and a director.  The specific amount of damages sought is to be proven at trial and is not specified. In August 2013, the court granted the Company’s motion to compel arbitration of these claims and therefore this action has  been dismissed.
	A hearing in the arbitration has been postponed pending certain procedures in the above Western Division action and may be delayed further to accommodate other third party civil and federal criminal proceedings alleging securities and wire fraud that have been brought against Mr. Kelly with respect to his prior employment and predating his service with the Company.
	The Company is reasonably confident in its defenses to Mr. Kelly’s and Mr. Cononi’s claims. Consequently, no provision or liability has been recorded for these claims as of September 30, 2013.  However, it is at least reasonably possible that the Company’s estimate of liability may change in the near term. Any payments by reason of an adverse determination in this matter will be charged to earnings in the period of determination.
	On October 10, 2013, a putative securities class action complaint was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering.  The complaint alleges that all defendants violated Sections 11 and 12(a)(2), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device.   This action seeks, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount. We believe this complaint is without merit and plan to defend ourselves vigorously.   Failure by us to obtain a favorable resolution of the claims set forth in the complaint could have a material adverse effect on our business, results of operations and financial condition.  Currently, the amount of such material adverse effect cannot be reasonably estimated, and no provision or liability has been recorded for these claims as of September 30, 2013.  The costs associated with defending and resolving the complaint and ultimate outcome cannot be predicted.  These matters are subject to inherent uncertainties and the actual cost, as well as the distraction from the conduct of our business, will depend upon many unknown factors and management’s view of these may change in the future.
	FDA Warning Letter
	On February 21, 2013, the Company received a Warning Letter (“Letter”) from the FDA regarding its Mammary Aspirate Specimen Cytology Test (MASCT) System and MASCT System Collection Test (together, the “System”).  The Letter arises from certain FDA findings during a July 2012 inspection, to which the Company responded in August 2012, explaining why the Company believed it was in compliance with applicable regulations and/or was implementing changes responsive to the findings of the FDA inspection.  The FDA alleges in the Letter that following 510(k) clearance of the MASCT System, the Company changed the System in a manner that requires submission of an additional 510(k) notification to the FDA.  Specifically, the FDA stated that the Instructions For Use (IFU) in the original 510(k) submission stated that the user must “Wash the collection membrane with fixative solution into the collection vial…” while the current IFU states “…apply one spray of Saccomanno’s Fixative to the collection membrane…” and that “this change fixes the NAF specimen to the filter paper rather than washing it into a collection vial.” At the time that the changes were made the Company determined and documented that the change could not significantly affect the safety or effectiveness of the MASCT System, and thus, that a new 510(k) was not required in accordance with the FDA’s guidance document entitled, “Deciding When to Submit a 510(k) for a Change to an Existing Device.”  The Letter also identified certain issues with respect to the Company’s marketing of the System and the Company’s compliance with FDA Good Manufacturing Practices (cGMP) regulations, among other matters. The Company responded to the Letter on March 13, 2013, and identified the corrective actions that had been made, or were otherwise underway The Company also filed a new 510(k) application for the MASCT System which was withdrawn in August 2013 after receiving feedback from the FDA.
	On October 4, 2013, the Company initiated a voluntary recall of the system to address FDA’s concerns regarding the modifications identified in the Letter. As a result of this recall, this product is currently not being marketed or distributed in the U.S.  The Company plans to prepare a new premarket notification or 510(k) application for submission to the FDA that covers the collection, preparation, and processing of NAF specimens at our laboratory and includes the spray method of fixing specimens to the collection membrane.
	To ensure that the 510(k) includes the information that FDA feels is appropriate, we have requested a pre-submission meeting with the FDA. This meeting is scheduled to be held on November 14, 2013. Once we understand what types of data FDA is seeking, we intend to submit the 510(k) shortly after the meeting.  Once filed we hope that the FDA will complete their review of our submission within 90 days; but of course we cannot predict if they will ask us for additional information or otherwise complete their review within the 90 days.
	The Company has recorded a loss contingency as of September 30, 2013 of $402,840 related to the estimated costs of the recall, including the estimated costs of pursuing the additional 510(k) clearance.  The recall and 510(k) process may take longer than expected and we may incur costs that we have not anticipated.  Accordingly, the actual amount of the loss contingency may be higher than we currently expect.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 12: RELATED PARTY TRANSACTIONS
	Loans from Officer
	On May 26, 2009, the Company borrowed $5,000 from its Chairman of the Board and Chief Executive Officer as a short-term, unsecured loan via verbal agreement and did not bear any interest. Commencing June 30, 2010, the loan was converted into a written Promissory Note bearing an annual interest rate of 10%, with a maturity date of December 31, 2010. This note was repaid in full on May 16, 2011 including approximately $439 of accrued interest.
	On June 30, 2010, the Company borrowed an additional $100,000 from its Chairman of the Board and Chief Executive Officer pursuant to a promissory note. The loan under the note was funded to the Company on July 12, 2010. The note bears a 10% interest rate per annum and carries a $4,000 loan origination fee which is accreted to the loan balance throughout the life of the loan. The $4,000 loan origination fee was fully accreted to the loan balance as of March 31, 2011 and December 31, 2010, and recorded as interest expense for the year ended December 31, 2010. This note (including the $4,000 origination fee) was repaid in full on May 19, 2011 including approximately $8,959 in accrued interest.
	On November 3, 2010, the Company entered into a line of credit agreement for borrowing up to $500,000 from its Chairman of the Board and Chief Executive Officer pursuant to a promissory note. The note bears a 10% interest rate per annum. An aggregate of $140,000 was funded to the Company under the line of credit as of March 31, 2011 which was repaid on May 31, 2011, including approximately $6,093 in accrued interest. As of December 31, 2011, the unpaid principal balance drawn from the line of credit was $5,078, which was fully repaid on March 31, 2012.
	On July 30, 2012, the Company entered into a line of credit agreement for borrowing up to $500,000 from its Chairman of the Board and Chief Executive Officer pursuant to a promissory note. The note bears a 12% interest rate per annum. An aggregate of $79,300 was funded to the Company under the line of credit as of December 31, 2012. The principal balance of $79,300 and interest of $1,440 was fully repaid on October 11, 2012.
	Exclusive License Agreement
	On July 27, 2009, the Company entered into an exclusive license agreement with Ensisheim Partners LLC (“Ensisheim”), an entity solely owned by the Chairman and Chief Executive Officer of the Company and the Chief Scientific Officer of the Company, who is also the wife of the Company’s Chairman and CEO. Pursuant to that agreement, Ensisheim granted the Company an exclusive, worldwide, perpetual, irrevocable, royalty-bearing, license to the MASCT System, with the right to grant and authorize sublicenses. The license agreement provided that the Company would pay Ensisheim a royalty equal to 2% of net sales revenue, with a minimum royalty of $12,500 per fiscal quarter during the term of the agreement, which would have increased to a minimum royalty of $25,000 per fiscal quarter beginning in the quarter in which the first commercial sale of a licensed product would have taken place. From inception through December 31, 2010, the Company had incurred $16,250 in patent-related expenses under the license agreement with Ensisheim, and $0 subsequent to December 31, 2010.
	On June 17, 2010, the Company and Ensisheim entered into an Assignment Agreement, whereby Ensisheim assigned to the Company all rights to the patents and patent applications underlying the MASCT System. Pursuant to the assignment, the Company will have all responsibility for prosecution, maintenance, and enforcement and will indemnify Ensisheim from any and all claims against the patent estate. Ensisheim retained no residual rights with respect to the patents and patent applications. In conjunction with the assignment, the Company terminated the exclusive license agreement between the Company and Ensisheim dated July 27, 2009. As a result of the termination, the Company has no further obligations with respect to royalty payments to Ensisheim due under the old licensing agreement. As a result, the $12,500 of patent royalty payable to Ensisheim recorded as accrued royalty payable at December 31, 2009 has been reversed through royalty expense during the second quarter of 2010.
	Commercial Lease Agreement
	On December 24, 2009, the Company entered into a commercial lease agreement with Ensisheim for office space located in Seattle, Washington. The lease provided for annual rent of $13,200, plus applicable sales tax. From inception through December 31, 2009, the Company incurred $248 of rent expense for the lease with security deposit of $1,100. For the period of January 1, 2010 through June 30, 2010, the Company incurred $6,600 of rent expense for the lease. On July 15, 2010 the Company and Ensisheim terminated the lease, effective July 1, 2010 and the Company commenced use of the facility rent free until April 1, 2011 when the commercial lease agreement the Company entered into with Sanders Properties, LLC became effective (see Note 11). The $1,100 security deposit paid to Ensisheim was received as of December 31, 2012.
	Executive Compensation
	On May 19, 2010, the Company entered into employment agreements with three executives, including its Chief Executive Officer, its former President, and its Chief Scientific Officer. The annual base salaries under each agreement were calculated based on combined consideration of the success of capital raise and the operating results of the Company, and capped at $360,000, $350,000, and $250,000, respectively for the three executives.
	On July 22, 2010, in connection with the resignation and departure of Robert L. Kelly, the President and a director, the Company entered into a consulting agreement with a limited liability company controlled by Mr. Kelly. Under the agreement, the Company was to receive consulting services relating to capital raising and investor relations. The agreement was terminated by the Company in September 2010, through which time a total of $30,000 consulting expense had been paid.
	On July 22, 2010, the Company restated and amended the employment agreements with its CEO and CSO. The agreements modified the base annual salary amounts to $250,000 and $200,000, respectively, effective retroactively to May 19, 2010. For the nine months ended September 30, 2012, salaries and bonuses of CEO and CSO amounted to $269,438 and $200,550, of which $134,719 and $200,550 were recorded to research and development expense, respectively. For the nine months ended September 30, 2013, salaries and bonuses of CEO and CSO amounted to $258,635 and $191,908, of which $129,316 and $191,908 were recorded to research and development expense, respectively.
	Share-Based Compensation
	The amended employment agreement with the CEO, entered into on July 22, 2010, granted options to purchase 250,000 shares (or 565,830 shares prior to the reverse stock-split on September 28, 2010) at a price of $5.00 per share, in consideration of his service to the Company. Of these options, 25% (or 62,500 shares) vested on December 31, 2010 with the remaining 75% (or 187,500 shares) to vest in equal quarterly installments over the next three years so long as the executive remains employed with the company. These options have five-year contractual terms.
	The amended employment agreement with the CSO, entered into on July 22, 2010, granted options to purchase 100,000 shares (or 226,332 shares prior to the reverse stock-split on September 28, 2010) at a price of $5.00 per share in consideration of her service to the Company. Of these options, 25% (or 25,000 shares) vested on December 31, 2010 with the remaining 75% (or 75,000 shares) to vest in equal quarterly installments over the next three years so long as the executive remains employed with the company. These options have five-year contractual terms.
	On April 4, 2011, 45,000 non-qualified stock options were granted under the 2010 Plan to Dr. Tim Hunkapiller for being a member of the Company’s Scientific Advisory Board and consulting services to be provided to the Company, at an exercise price of $1.25 per share. These options have a ten-year contractual term and shall vest as follows:
		(i)	11,250 option shares shall vest ninety (90) days after the date of grant;
		(ii)	11,000 option shares shall vest one hundred and eighty (180) days after the date of grant;
		(iii)	11,500 option shares shall vest two hundred and seventy (270) days after the date of grant;
		(iv)	11,250 option shares shall vest three hundred and sixty (360) days after the date of grant.
	On September 1, 2011, 219,000 incentive stock options were granted under the 2010 Plan to employees and officers as part of their employment agreements, at an exercise price of $1.25 per share. These options have a ten-year contractual term and shall vest and become exercisable as follows:
		(i)	twenty-five percent (25%) of the underlying shares on the first anniversary of the date of grant; and
		(ii)	forty eighth (1/48) of the underlying shares monthly thereafter.
	On September 1, 2011, 200,000 non-qualified stock options were granted under the 2010 Plan to non-employee directors for services to be provided to the Company, at an exercise price of $1.25 per share. These options have a ten-year contractual term and shall vest and become exercisable as follows:
		(i)	80,000 option shares shall vest on September 1, 2011;
		(ii)	30,000 options shares shall vest on December 1, 2011;
		(iii)	30,000 options shares shall vest on March 1, 2012;
		(iv)	30,000 options shares shall vest on June 1, 2012;
		(v)	30,000 options shares shall vest on September 1, 2012.
	On April 30, 2012, 19,757 non-qualified stock options were granted under the 2010 Plan to non-employee directors for serving as directors of the Company, at an exercise price of $6.00 per share. These options have a ten-year contractual term and shall vest and become exercisable in full immediately as of the grant date.
	On December 17, 2012, 228,000 non-qualified stock options were granted under the 2010 Plan to employees as part of their employment agreements, at an exercise price of $4.24 per share. On December 20, 2012, 200,000 non-qualified stock options were granted outside of the 2010 Plan, but governed in all respects by the 2010 Plan, to an employee as part of his employment agreement, at an exercise price of $4.11 per share. These options each have a ten-year contractual term and shall vest and become exercisable as follows:
		(i)	twenty-five percent (25%) of the underlying shares on the first anniversary of the date employment commenced; and
		(ii)	one-sixteenth (1/16) of the underlying shares quarterly thereafter.
	In accordance with the guidance provided in ASC Topic 718, Stock Compensation (formerly SFAS 123R), the compensation costs associated with these options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized a compensation expense of $1,187,716 and $96,251 for the nine months ended September 30, 2013 and 2012, respectively.
	The Company estimated the fair value of these options using the Black-Scholes-Merton option pricing model based on the following weighted-average assumptions:
	2010 through December 2012		Employee		Employee &		Directors	CEO &
					Officers			CSO
	Date of Grant		December 2012		September 2011		April 2012 – September 2011	July 2010
	Fair value of common stock on date of grant		$4.11-$4.24(D)		$0.9060(B)		$0.9060 (B &C )	$2.7560(A)
	Exercise price of the options		$4.11 - $4.24		$1.25		$1.25-$6.00	$5.00
	Expected life of the options (years)		5.74 - 6.11		5.65		5.00 – 5.65	3.33
	Dividend yield		0.00%		0.00%		0.00%	0.00%
	Expected volatility		42.44 – 44.58%		53.90%		53.90-62.46%	58.59%
	Risk-free interest rate		0.91-0.99%		1.08%		0.89 – 1.08%	1.03%
	Expected forfeiture per year (%)		10.00%		10.00%		0.00%	0.00%
	Weighted average fair value of the options per unit		$1.7426-$1.7842		$0.36		$0.3579-$3.0367	$0.67
	Year To Date September 2013		Employee		Employee &		Directors	CEO &
					Officers			CSO
	Date of Grant		January - August 2013		January - June 2013		May 2013	March 2013
	Fair value of common stock on date of grant(E)		$3.95 - $5.19(D )		$4.11 - $4.58(D)		$6.59 (D)	$6.57 (D )
	Exercise price of the options		$3.95 - $5.19		$4.11 - $4.58		$6.59	$6.57
	Expected life of the options (years)		6.09 - 6.11		5.00 – 6.11		5.00 – 5.31	5
	Dividend yield		0.00%		0.00%		0.00%	0.00%
	Expected volatility		40.73 - 40.92%		40.96 - 41.05%		41.06-41.09%	47.09%
	Risk-free interest rate		1.73 -1.97%		1.03-1.36%		0.73 - 0.84%	1.13%
	Expected forfeiture per year (%)		10.00%		10.00%		10.00%	0.00%
	Weighted average fair value of the options per unit		$1.35 - $2.18		$1.69 - $1.89		$2.41 - $2.49	$2.70
		(A)	The fair value of the Company's common stock was derived implicitly from the public offering filed in March 2010 at $3.00 per share and from the terms of an underwritten offering contemplated in July 2010 at $6.00 per Unit that was filed in October 2010, with $2.756 per share being allocated to common stock using an iterative approach in order for the combined fair value of the common stock and warrants to equal the amount of consideration to be received for the offering.
		(B)	The fair value of the Company's common stock was derived implicitly from the Private Placement during April through June 2011 at $1.25 per Unit, wherein one Unit was comprised of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $1.60 per share.
		(C)	The fair value of the Company's common stock was derived implicitly from the public offering filed in February 2012 at $6.00 per share.
	(D)	The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.
In October 2010, the Company filed a Registration Statement on Form S-1 with the SEC. However, the market for early stage investments in medical technology transactions had deteriorated between mid-2010 and early 2011. In addition, the Company’s ability to negotiate with potential investors was limited. The Company’s cash position had also diminished since the summer of 2010 and the founders of the Company were unable to finance the Company at the level needed for growth. The withdrawal of the Registration Statement in February 2011 further weakened the impression of the Company in the market. The fair value of the Company’s common stock decreased from $2.756 in 2010 to $0.906 in 2011 primarily because the grants in 2011 relied on the arm’s-length negotiation of the private placement financing (for illiquid stock) as opposed to relying on an anticipated initial public offering (of publicly-traded stock), as was the case in 2010. The private placement transactions were between the company and over 200 accredited investors and ascribed a value of $0.906 to the Company’s common stock.
	Fair value hierarchy of the above assumptions can be categorized as follows:
-1	There were no Level 1 inputs.
-2	Level 2 inputs include:
Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the options.
-3	Level 3 inputs include:
Expected lives- The expected lives of options granted were derived from the output of the option valuation model and represented the period of time that options granted are expected to be outstanding.
Expected forfeitures per year- The expected forfeitures are estimated at the dates of grant and will be revised in subsequent periods pursuant to actual forfeitures, if significantly different from the previous estimates.
Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the options using the calculated value method. The Company identified five to seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.
The estimates of fair value from the model are theoretical values of stock options and changes in the assumptions used in the model could result in materially different fair value estimates. The actual value of the stock options will depend on the market value of the Company’s common stock when the stock options are exercised.
Notwithstanding that the fair market value of the Company’s common stock in September 2011 was $0.906 per share, the Company filed a Registration Statement on Form S-1 in February 2012 to offer shares of its common stock at $5.00 to $7.00 per share. This increase in share value is justified by the accomplishments achieved by the Company between September 2011 and February 2012. Specifically, the MASCT System manufacturing had been completed, supplies for the Field Experience Trial were completed and the Company had established an FDA-compliant inventory and warehousing facility. Further, the National Reference Laboratory for Breast Health, the Company’s wholly-owned subsidiary, was established as a Delaware corporation, was equipped and staffed, and the protocols and procedures needed to be a CLIA-registered facility were put in place. Moreover, the ForeCYTE test, which involves cytopathology and five biomarkers of hyperplasia and one biomarker of sample integrity, was completed, tested, and validated to CLIA standards. Computer hardware and software was acquired, set up, made operational, and the ForeCYTE report template, with unique reporting information for the requesting physician and a patient letter template, were created. The company explored and identified a technology for the ArgusCYTE test, negotiated a supply agreement with the supplier, and tested and validated the test. An ArgusCYTE report template was also established and a new reporting scheme invented and a patent application filed.
Further, the Company negotiated the acquisition of the FullCYTE Microcatheter System from Hologics, reestablished the supply chain and began preparing for a commercial launch later in 2012 or early 2013. In doing so, the Company increased its U.S. patent portfolio from 5 to 31 and its total portfolio of patents and applications to over 120. The Hologic patent estate also contains the key patents that permit microcatheter-based intraductal treatment of cancer and pre-cancer. The Company also prepared marketing documents for the launch of the ForeCYTE and ArgusCYTE tests, which occurred in December 2011. The Company launched a clinical trial of the FullCYTE microcatheter to establish the feasibility of performing Next Generation Sequencing on the samples obtained with the microcatheter, negotiated the acquisition of the NextCYTE technology, and is conducting a study of the utility of the technology in providing superior information in the setting of cancer diagnosis and treatment selection.
The Company also established third-party relationships to perform the reimbursement billing in anticipation of the commercial launch and to permit electronic remittance of testing revenue. The Company commenced a Field Test Experience limited launch of both the ForeCYTE and ArgusCYTE tests on schedule in December 2011 and has seen significant market acceptance of both tests from the doctors and clinics using the tests. The Company passed a CLIA inspection and became CLIA-certified, has obtained several state licenses and has pending applications in all remaining states where licensure is required. Finally, the Board of Directors and scientific advisory board were each strengthened with the addition of key new executives and scientists.
The Board of Directors considered each of the foregoing achievements, and considered input from the Company’s investment bankers, in determining that the value of the Company supports a valuation of $5.00 to $7.00 per share of the Company’s common stock.
Options issued and outstanding as of September 30, 2013 and their activities during the nine months then ended are as follows:
		Number of			Weighted-		Weighted-
		Underlying			Average		Average
		Shares			Exercise		Contractual
					Price Per		Life
					Share		Remaining
							in
							Years
Outstanding as of January 1, 2013			1,052,137		$	3.79
Granted			1,425,394			5.02
Expired			-3,812			4.99
Forfeited			-221,522			4.21
Exercised			-5,546			1.79
Outstanding as of September 30, 2013			2,246,651			4.53		8.87
Exercisable as of September 30, 2013			1,044,549			4.54		8.21
Vested and expected to vest (1)			2,090,475			4.54		8.83
(1) vested shares and unvested shares after a forfeiture rate is applied.
As of September 30, 2013 and December 31, 2012, the aggregate intrinsic value of options outstanding was $3,604,669 and $1,150,416, respectively.

ASSET_PURCHASE

ASSET PURCHASE	9 Months Ended
	Sep. 30, 2013
Asset Purchase [Abstract]	'
Schedule of Asset Purchase [Text Block]	'
	NOTE 13: ASSET PURCHASE
	On September 30, 2012, the Company entered into an asset purchase agreement with Acueity Healthcare, Inc (“Acueity”) to acquire substantially all of the assets of Acueity. Through the asset purchase, the Company acquired 35 issued patents (18 issued in the U.S. and 17 issued in foreign countries), 41 patent applications (32 in the U.S. and 9 in foreign countries), six 510(k) FDA marketing authorizations related to the manufacturing, use, and sale of the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $400,000; no liabilities were assumed in the transaction. In consideration for the assets, the Company issued 862,500 shares of common stock, valued at $5.00 per share, the offering price listed on the prospectus filed pursuant to Rule 424(b)(4) on November 9, 2012, and warrants to purchase up to 325,000 shares of common stock at an exercise price of $5.00 per share, to the shareholders of Acueity, subject to a six-month lock up agreement which has since lapsed. The warrants, which have a five-year term, do not have a cashless exercise provision. The warrants were valued at $2.3457 per warrant, using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk-free rates) necessary to determine the fair value of the warrants (see Note 8). There are no future financial obligations from the Company to Acueity from the commercialization of the acquired assets.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 14: SUBSEQUENT EVENTS
	Voluntary Product Recall
	On October 4, 2013 we initiated a voluntary recall to remove the ForeCYTE Breast Health Test and the MASCT device from the market. This voluntary recall includes the MASCT System Kit and Patient Sample Kit. The vast majority of these products (approximately ninety percent) are in inventory with our distributors and the remaining quantities are at customer sites across the United States. Distributors and customers have been instructed to stop using affected products and return them to Atossa immediately.
	The purpose of this voluntary recall is to address concerns raised by the FDA in a Warning Letter received by Atossa in February 2013. In that Warning Letter, the  FDA raised concerns about (1) the current instructions for use (IFU); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the NAF specimen collection process identified in the current IFU. We are in the process of removing existing product from the market.
	We are working with the FDA on this matter and this voluntary recall. We have notified distributors and customers by certified mail and we are arranging for the return of all recalled products.  We plan to prepare a new premarket notification or 510(k) application for submission to the FDA that covers the collection, preparation, and processing of NAF specimens at our laboratory and includes the spray method of fixing specimens to the collection membrane. However, we cannot market or distribute the modified product in the U.S. unless or until the new 510(k) is cleared by the FDA.
	To ensure that the 510(k) includes the information that FDA feels is appropriate, we have requested a pre-submission meeting with the FDA.  This meeting is scheduled to be held on November 14, 2013.   Once we understand what types of data FDA is seeking, we intend to submit the 510(k) shortly after the meeting.   Once filed we hope that the FDA will complete their review of our submission within 90 days; but of course we cannot predict if they will ask us for additional information or otherwise complete their review within the 90 days.
	The Company has recorded a loss contingency as of September 30, 2013 of $402,840 related to the estimated costs of the recall, including the estimated costs of pursuing the additional 510(k) clearance.  The recall and 510(k) process may take longer than expected and we may incur costs that we have not anticipated.  Accordingly, the actual amount of the loss contingency may be higher than we currently expect.
	Aspire Common Stock Purchase Agreement
	From the October 1, 2013 through November 7, 2013, the Company has sold 200,000 shares of common stock to Aspire Capital with gross proceeds to the Company of $349,670, pursuant to the terms of the Common Stock Purchase Agreement with Aspire dated March 27, 2013.  The March 27, 2013 Common Stock Purchase Agreement with Aspire Capital was terminated on November 8, 2013 and on that date we entered into a new stock purchase agreement with Aspire Capital Fund, LLC.  The new stock purchase agreement provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire is committed to purchase up to an aggregate of $25 million of shares of our common stock over the 30 month term of the agreement. We cannot, however, sell any shares to Aspire under the new agreement unless and until a new registration statement is filed with and declared effective by the SEC.

SUMMARY_OF_ACCOUNTING_POLICIES1

SUMMARY OF ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation:
	The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiary NRLBH. All significant intercompany account balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Pronouncements:
	The Company has adopted all recently issued accounting pronouncements that management believes to be applicable to the Company. The adoption of these accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition:
	Overview
	The Company recognizes product and service revenue in accordance with GAAP when the following overall fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or the service has been performed, (iii) the Company’s price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured.
	Product Revenue
	The Company recognizes revenue for sales of the MASCT kits and devices on an accrual basis for sales to distributors when the above four criteria are met. For sales of MASCT kits and devices directly to physicians, the revenue is typically recognized upon receipt of cash as the Company has an insufficient sales history on which to determine the collectability. Shipping documents and the completion of any customer acceptance requirements, when applicable, will be used to verify product delivery. The Company will assess whether a price is fixed or determinable based upon the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. For sales directly to physicians, once a history of sales and collectability has been established, the Company will recognize revenue on an accrual basis with an offsetting reserve for doubtful accounts based on the history during the initial sales period.
	Service Revenue
	The Company records revenue for diagnostic testing on an accrual basis at the Medicare allowed and invoiced amount. Amounts invoiced above the Medicare amount, namely non-Medicare, are not recognized on an accrual basis and instead are recognized on a cash basis as received. Diagnostic testing revenue at the Medicare rate is recognized upon completion of the test, communication of results to the patient’s physician, and when collectability is reasonably assured. Customer purchase orders and/or contracts will generally be used to determine the existence of an arrangement. Once the Company has historical sales and can determine the proper amount to recognize as uncollectible, it will then begin to recognize the entire amount, both Medicare and non-Medicare billing on an accrual basis, with an offsetting allowance for doubtful accounts recorded based on history. The Company estimates it will utilize the diagnostic testing revenue history to determine a proper allowance for doubtful accounts beginning in 2014.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents:
	Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates:
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	'
	Accounts Receivable:
	Accounts receivable are recorded at net realizable value consisting of the carrying amount less allowance for doubtful accounts, as needed. The Company assesses the collectability of accounts receivable based primarily upon the creditworthiness of the customer as determined by credit checks and analysis, as well as the customer’s payment history. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company’s allowance for doubtful accounts and bad debt expenses as of September 30, 2013 and December 31, 2012 was $228,841 and $0, respectively.
Inventory, Policy [Policy Text Block]	'
	Inventories:
	The Company’s inventories are stated at lower of cost or market. Cost is determined on a moving-average basis. Costs of inventories include purchase and related costs incurred in delivering the products to their present location and condition. Market value is determined by reference to selling prices after the balance sheet date or to management’s estimates based on prevailing market conditions. Inherent in the lower of cost or market calculation are several significant judgments based on a review of the aging of the inventory, inventory movement of products, economic conditions, and replacement costs. Because the sales price of the MASCT System was substantially lower than its cost for the period ended September 30, 2013 and December 31, 2012, resulting in the net realizable value of the MASCT System being determined at zero as of September 30, 2013 and December 31, 2012, through taking the average sales price subtracted by selling expenses per unit. The Company assessed and recorded $0 and $29,884 loss on reduction of inventory to the lower of cost or market for the nine months ended September 30, 2013 and for the year ended December 31, 2012, respectively. Additionally, management periodically evaluates the composition of its inventories at least quarterly to identify slow-moving and obsolete inventories to determine if any valuation allowance is required. As of September 30, 2013 and December 31, 2012, management had identified no slow moving or obsolete inventory. The Company outsources product manufacturing to outside manufacturer contactors.  The ownership of the goods transfers from the manufacturer to the Company’s customer at the time the products are shipped to the customers. As of September 30, 2013, there are no inventories on our books.
	The Company provides, either directly or through distributors, the ForeCYTE testing specimen collection kits to doctors with our MASCT System for doctors to collect specimens that are returned to the NRLBH for diagnostic analysis. These collection kits are considered part of the MASCT System. The Company’s direct sales personnel distributes the kits directly to physicians free of charge, or by offering a rebate to physicians. The Company has not intended to deem the kits as a primary product line due to their nominal cost and value per unit. As a result, the kits are immediately expensed and recorded as selling expense upon purchasing of the kits.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property, plant, and equipment:
	Property, plant and equipment are stated at cost less accumulated depreciation.  Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized.  When property, plant and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.
	Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Machinery and equipment		5
	Leasehold improvements		2.083
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	'
	Intangible assets:
	Intangible assets consist of intellectual property and software acquired in the Acueity asset purchase. At least annually, we evaluate purchased intangibles for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense. There was no impairment of intangible assets as of and for the nine months ended September 30, 2013 and year ended December 31, 2012, respectively.
	Amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Patents		14-Sep
	Software		3
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Expenses:
	Research and development costs are generally expensed as incurred. The Company’s research and development expenses consist of costs incurred for internal and external research and development.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-Based Payments:
	In December 2004, the Financial Accounting Standards Board, or the FASB, issued the Statement of Financial Accounting Standards, or SFAS, No. 123(R), “Share-Based Payment”, which replaces SFAS No. 123 and supersedes APB Opinion No. 25. SFAS No. 123(R) is now included in the FASB’s ASC Topic 718, “Compensation – Stock Compensation.” Under SFAS No. 123(R), companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees or independent contractors are required to provide services. Share-based compensation arrangements include stock options and warrants, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. In March 2005, the SEC issued Staff Accounting Bulletin No. 107, or SAB 107, which expresses views of the staff regarding the interaction between SFAS No. 123(R) and certain SEC rules and regulations and provides the staff’s views regarding the valuation of share-based payment arrangements for public companies. SFAS No. 123(R) permits public companies to adopt its requirements using one of two methods. On April 14, 2005, the SEC adopted a new rule amending the compliance dates for SFAS No. 123(R). Companies may elect to apply this statement either prospectively, or on a modified version of retrospective application under which financial statements for prior periods are adjusted on a basis consistent with the pro forma disclosures required for those periods under SFAS No. 123.
	The Company has fully adopted the provisions of FASB ASC 718 and related interpretations as provided by SAB 107. As such, compensation cost is measured on the date of grant as the fair value of the share-based payments. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

SUMMARY_OF_ACCOUNTING_POLICIES2

SUMMARY OF ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Property, Plant and Equipment, Useful Life [Table Text Block]	'
	Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Machinery and equipment		5
	Leasehold improvements		2.083
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Patents		14-Sep
	Software		3

PREPAID_EXPENSES_Tables

PREPAID EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	'
	Prepaid expenses consisted of the following:
		September 30,		December 31,
		2013		2012
	Prepaid stock purchase agreement service fee	$	508,442	$	-
	Prepaid insurance		27,445		62,551
	Prepaid hardware/software maintenance and support service fee		23,499		20,000
	Prepaid payroll taxes		-		40,082
		$	559,386	$	122,633

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT, AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property, plant and equipment consisted of the following:
		September 30,		December 31,
		2013		2012
	Machinery and equipment	$	269,771	$	97,383
	Leasehold improvements		93,665		93,665
	Capitalized new product development costs		173,766		-
	Less: Accumulated depreciation		-93,930		-31,081
	Property, plant, and equipment, net	$	443,272	$	159,967

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets and Goodwill [Table Text Block]	'
	Intangible assets consisted of the following:
		September 30,		December 31,
		2013		2012
	Patents	$	4,704,853	$	4,704,853
	Software		105,133		50,466
	Less: Accumulated amortization		-402,928		-115,095
		$	4,407,058	$	4,640,224
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Future estimated amortization expenses as of September 30, 2013 for the five succeeding years is as follows:
	As of September 30,	Amounts
	2014	$	393,073
	2015		381,331
	2016		378,781
	2017		363,902
	2018		363,028
	Thereafter		2,526,943
		$	4,407,058

PAYROLL_LIABILITIES_Tables

PAYROLL LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Payroll liabilities consisted of the following:
		September 30,		December 31,
		2013		2012
	Accrued bonus payable	$	297,290	$	189,131
	Accrued payroll liabilities		40,318		-
	Accrued payroll tax liabilities		19,881		18,865
		$	357,489	$	207,996

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2013
Investor, Placement Agent1 and Placement Agent2 Warrants [Member]	'
Schedule of Fair Value of Warrants [Table Text Block]	'
	The Investor Warrants and the Placement Agent Warrants were initially valued at $1,808,025 or $0.344 per warrant, $228,712 or $0.290 per warrant, and $267,164 or $0.339 per warrant, respectively. The following tables reflect assumptions used to determine the fair value of the Warrants:
		Fair			April-June2011			December 2011
		Value			Investor Warrants			Placement Agent			Placement
		Hierarchy						Warrants			Agent
		Level									Warrants
	Indexed shares					5,256,800			788,520			788,520
	Exercise price				$	1.6		$	1.6		$	1.25
	Significant assumptions:
	Stock price		3		$	0.906		$	0.906		$	0.906
	Remaining term		3			6 years			6 years			6 years
	Risk free rate		2			2.49	%		1.12	%		1.12	%
	Expected volatility		3			53.55	%		54.21	%		54.21	%
	Fair value hierarchy of the above assumptions can be categorized as follows:
		-1	There were no Level 1 inputs.
		-2	Level 2 inputs include:
	Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.
		-3	Level 3 inputs include:
	Stock price- The Company’s common stock was not publicly traded at the time the Warrants were issued. Therefore, the stock price was determined implicitly from an iterative process in order for the combined fair value of the common stock and the warrants to equal the amount of proceeds received in the Private Placement, based upon the assumption that the Private Placement was the result of an arm’s length transaction.
	Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.
	Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.
Acueity Warrants [Member]	'
Schedule of Fair Value of Warrants [Table Text Block]	'
	The Acueity Warrants were valued at $762,353 or $2.3457 per warrant. The following tables reflect assumptions used to determine the fair value of the Warrants:
			Fair			September 2012
			Value
			Hierarchy
			Level			Acueity Warrants
	Indexed shares						325,000
	Exercise price					$	5
	Significant assumptions:
	Stock price			3		$	5
	Remaining term			3			5 years
	Risk free rate			2			0.62	%
	Expected volatility			3			56.54	%
	Fair value hierarchy of the above assumptions can be categorized as follows:
		-1	There were no Level 1 inputs.
		-2	Level 2 inputs include:
	Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.
		-3	Level 3 inputs include:
	Stock price- The Company’s common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).
	Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.
	Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Operating Leases of Lessee Disclosure [Table Text Block]	'
	The future minimum lease payments due subsequent to September 30, 2013 under all non-cancelable operating leases for the next five years are as follows:
	As of September 30,	Amount
	2014	$	380,767
	2015		62,451
	2016		-
	2017		-
	2018		-
	Thereafter		-
	Total minimum lease payments	$	443,218

RELATED_PARTY_TRANSACTIONS_Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The Company estimated the fair value of these options using the Black-Scholes-Merton option pricing model based on the following weighted-average assumptions:
	2010 through December 2012		Employee		Employee &		Directors	CEO &
					Officers			CSO
	Date of Grant		December 2012		September 2011		April 2012 – September 2011	July 2010
	Fair value of common stock on date of grant		$4.11-$4.24(D)		$0.9060(B)		$0.9060 (B &C )	$2.7560(A)
	Exercise price of the options		$4.11 - $4.24		$1.25		$1.25-$6.00	$5.00
	Expected life of the options (years)		5.74 - 6.11		5.65		5.00 – 5.65	3.33
	Dividend yield		0.00%		0.00%		0.00%	0.00%
	Expected volatility		42.44 – 44.58%		53.90%		53.90-62.46%	58.59%
	Risk-free interest rate		0.91-0.99%		1.08%		0.89 – 1.08%	1.03%
	Expected forfeiture per year (%)		10.00%		10.00%		0.00%	0.00%
	Weighted average fair value of the options per unit		$1.7426-$1.7842		$0.36		$0.3579-$3.0367	$0.67
	Year To Date September 2013		Employee		Employee &		Directors	CEO &
					Officers			CSO
	Date of Grant		January - August 2013		January - June 2013		May 2013	March 2013
	Fair value of common stock on date of grant(E)		$3.95 - $5.19(D )		$4.11 - $4.58(D)		$6.59 (D)	$6.57 (D )
	Exercise price of the options		$3.95 - $5.19		$4.11 - $4.58		$6.59	$6.57
	Expected life of the options (years)		6.09 - 6.11		5.00 – 6.11		5.00 – 5.31	5
	Dividend yield		0.00%		0.00%		0.00%	0.00%
	Expected volatility		40.73 - 40.92%		40.96 - 41.05%		41.06-41.09%	47.09%
	Risk-free interest rate		1.73 -1.97%		1.03-1.36%		0.73 - 0.84%	1.13%
	Expected forfeiture per year (%)		10.00%		10.00%		10.00%	0.00%
	Weighted average fair value of the options per unit		$1.35 - $2.18		$1.69 - $1.89		$2.41 - $2.49	$2.70
		(A)	The fair value of the Company's common stock was derived implicitly from the public offering filed in March 2010 at $3.00 per share and from the terms of an underwritten offering contemplated in July 2010 at $6.00 per Unit that was filed in October 2010, with $2.756 per share being allocated to common stock using an iterative approach in order for the combined fair value of the common stock and warrants to equal the amount of consideration to be received for the offering.
		(B)	The fair value of the Company's common stock was derived implicitly from the Private Placement during April through June 2011 at $1.25 per Unit, wherein one Unit was comprised of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $1.60 per share.
		(C)	The fair value of the Company's common stock was derived implicitly from the public offering filed in February 2012 at $6.00 per share.
		(D)	The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	Options issued and outstanding as of September 30, 2013 and their activities during the nine months then ended are as follows:
			Number of			Weighted-		Weighted-
			Underlying			Average		Average
			Shares			Exercise		Contractual
						Price Per		Life
						Share		Remaining
								in
								Years
	Outstanding as of January 1, 2013			1,052,137		$	3.79
	Granted			1,425,394			5.02
	Expired			-3,812			4.99
	Forfeited			-221,522			4.21
	Exercised			-5,546			1.79
	Outstanding as of September 30, 2013			2,246,651			4.53		8.87
	Exercisable as of September 30, 2013			1,044,549			4.54		8.21
	Vested and expected to vest (1)			2,090,475			4.54		8.83
	(1) vested shares and unvested shares after a forfeiture rate is applied.

NATURE_OF_OPERATIONS_Details_T

NATURE OF OPERATIONS (Details Textual) (USD $)	3 Months Ended		9 Months Ended		53 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenue, Net	$76,597	$105,576	$585,345	$383,386	$1,068,687
Cash Acquired from Acquisition	'	'	'	$400,000	'

SUMMARY_OF_ACCOUNTING_POLICIES3

SUMMARY OF ACCOUNTING POLICIES (Details)	9 Months Ended
	Sep. 30, 2013
Machinery and Equipment [Member]	'
Property, Plant and Equipment, Useful Life	'5 years
Leasehold Improvements [Member]	'
Property, Plant and Equipment, Useful Life	'2 years 30 days

SUMMARY_OF_ACCOUNTING_POLICIES4

SUMMARY OF ACCOUNTING POLICIES (Details 1)	9 Months Ended
	Sep. 30, 2013
Patents [Member]	'
Finite-Lived Intangible Asset, Useful Life	'9 years
Patents [Member] | Minimum [Member]	'
Finite-Lived Intangible Asset, Useful Life	'9 years
Patents [Member] | Maximum [Member]	'
Finite-Lived Intangible Asset, Useful Life	'14 years
Computer Software, Intangible Asset [Member]	'
Finite-Lived Intangible Asset, Useful Life	'3 years

SUMMARY_OF_ACCOUNTING_POLICIES5

SUMMARY OF ACCOUNTING POLICIES (Details Textual) (USD $)	9 Months Ended		12 Months Ended	53 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013
Loss on reduction of inventory to LCM	$0	$29,884	$29,884	$121,910
Allowance for Doubtful Accounts Receivable	$228,841	'	$0	$228,841

PREPAID_EXPENSES_Details

PREPAID EXPENSES (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Prepaid Stock Purchase Agreement Service Fee	$508,442	$0
Prepaid Insurance	27,445	62,551
Prepaid Hardware/Software Maintenance and Support Service Fee	23,499	20,000
Prepaid Payroll Taxes	0	40,082
Prepaid expense	$559,386	$122,633

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT, AND EQUIPMENT (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Machinery and equipment	$269,771	$97,383
Leasehold Improvements	93,665	93,665
Capitalized new product development costs	173,766	0
Less: Accumulated depreciation	-93,930	-31,081
Property, plant, and equipment, net	$443,272	$159,967

PROPERTY_PLANT_AND_EQUIPMENT_D1

PROPERTY, PLANT, AND EQUIPMENT (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Depreciation	$62,849	$12,970

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Patents	$4,704,853	$4,704,853
Software	105,133	50,466
Less: Accumulated amortization	-402,928	-115,095
Intangible assets, net	$4,407,058	$4,640,224

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Sep. 30, 2013	Dec. 31, 2012
2014	$393,073	'
2015	381,331	'
2016	378,781	'
2017	363,902	'
2018	363,028	'
Thereafter	2,526,943	'
Intangible assets, net	$4,407,058	$4,640,224

INTANGIBLE_ASSETS_Details_Text

INTANGIBLE ASSETS (Details Textual) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
			Computer Software, Intangible Asset [Member]	Computer Software, Intangible Asset [Member]	Patents [Member]	Patents [Member]	Patents [Member]	Patents [Member]	Laboratory software [Member]	Newly developed website [Member]
							Minimum [Member]	Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	'	'	'3 years	'	'9 years	'	'9 years	'14 years	'	'
Amortization of Intangible Assets	'	'	$15,322	$12,616	$272,511	$0	'	'	'	'
Capitalized Computer Software, Gross	$105,133	$50,466	'	'	'	'	'	'	$58,000	$31,500

PAYROLL_LIABILITIES_Details

PAYROLL LIABILITIES (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accrued bonus payable	$297,290	$189,131
Accrued payroll liabilities	40,318	0
Accrued payroll tax liabilities	19,881	18,865
Payroll liabilities	$357,489	$207,996

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)

Sep. 30, 2012

Dec. 30, 2011

Dec. 30, 2011

Jun. 30, 2011

Dec. 31, 2011

Dec. 30, 2011

Dec. 31, 2011

Dec. 30, 2011

Jun. 30, 2011

Dec. 31, 2011

Dec. 31, 2011

Jun. 30, 2011

Placement Agent1 [Member]

Placement Agent2 [Member]

Investor Warrants [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Placement Agent1 [Member]

Placement Agent1 [Member]

Placement Agent2 [Member]

Placement Agent2 [Member]

Investor Warrants [Member]

Placement Agent1 [Member]

Placement Agent2 [Member]

Investor Warrants [Member]

Indexed shares

'

788,520

788,520

5,256,800

'

'

'

'

'

'

'

'

Exercise price

'

$1.60

$1.25

$1.60

'

'

'

'

'

'

'

'

Significant assumptions:

'

'

'

'

'

'

'

'

'

'

'

'

Stock price

$5

'

'

'

'

$0.91

[1]

'

$0.91

[1]

$0.91

[1]

'

'

'

Remaining term

'

'

'

'

'6 years

[2]

'

'6 years

[2]

'

'6 years

[2]

'

'

'

Risk free rate

'

'

'

'

'

'

'

'

'

1.12%

[3]

1.12%

[3]

2.49%

[3]

Expected volatility

'

'

'

'

54.21%

[4]

'

54.21%

[4]

'

53.55%

[4]

'

'

'

[1]

Stock price- The Companybs common stock was not publicly traded at the time the Warrants were issued. Therefore, the stock price was determined implicitly from an iterative process in order for the combined fair value of the common stock and the warrants to equal the amount of proceeds received in the Private Placement, based upon the assumption that the Private Placement was the result of an armbs length transaction.

[2]

Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.

[3]

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

[4]

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entitiesb share prices in calculating the expected volatility appropriate to the Company.

STOCKHOLDERS_EQUITY_Details_1

STOCKHOLDERS' EQUITY (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2012
Significant assumptions:	'
Stock price	$5
Acueity Warrants [Member]	'
Indexed shares	325,000
Exercise price	$5
Acueity Warrants [Member] | Fair Value, Inputs, Level 3 [Member]	'
Significant assumptions:	'
Stock price	$5	[1]
Remaining term	'5 years	[2]
Expected volatility	56.54%	[3]
Acueity Warrants [Member] | Fair Value, Inputs, Level 2 [Member]	'
Significant assumptions:	'
Risk free rate	0.62%	[4]
[1]	Stock price- The Companybs common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).
[2]	Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.
[3]	Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entitiesb share prices in calculating the expected volatility appropriate to the Company.
[4]	Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

STOCKHOLDERS_EQUITY_Details_Te

STOCKHOLDERS' EQUITY (Details Textual) (USD $)

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Sep. 28, 2010

Sep. 30, 2010

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 28, 2010

Sep. 30, 2013

Sep. 30, 2013

Jan. 31, 2013

Jan. 31, 2012

Jun. 30, 2011

Sep. 30, 2013

Jun. 30, 2011

Jun. 30, 2011

Sep. 30, 2013

Jun. 30, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 28, 2010

Apr. 29, 2009

Apr. 29, 2009

Apr. 29, 2009

Apr. 29, 2009

Apr. 29, 2009

Apr. 29, 2009

Sep. 30, 2013

Sep. 30, 2013

Stock Option and Incentive Plan 2010 [Member]

Stock Option and Incentive Plan 2010 [Member]

Stock Option and Incentive Plan 2010 [Member]

Stock Option and Incentive Plan 2010 [Member]

Stock Option and Incentive Plan 2010 [Member]

Private Placement [Member]

Private Placement [Member]

Securities Purchase Agreements, Investor Warrants [Member]

Placement Agent Additional Warrants [Member]

Placement Agent1 [Member]

Placement Agent Warrants [Member]

Placement Agent2 [Member]

Acueity Warrants [Member]

Acueity Warrants [Member]

Prior to Reverse Share Split on September 28, 2010 [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Ensisheim Partners Llc [Member]

Ensisheim Partners Llc [Member]

Manistee Ventures Llc [Member]

Manistee Ventures Llc [Member]

Investor [Member]

Aspire Capital Fund, Llc [Member]

Stock Option and Incentive Plan 2010 [Member]

Prior to Reverse Share Split on September 28, 2010 [Member]

Prior to Reverse Share Split on September 28, 2010 [Member]

Prior to Reverse Share Split on September 28, 2010 [Member]

Placement Agent1 [Member]

Total Shares Authorized

'

'

'

85,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

'

'

'

75,000,000

75,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share (in dollars per share)

'

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

'

'

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Par or Stated Value Per Share (in dollars per share)

'

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders' Equity, Reverse Stock Split

'1-for-2.26332

'1-for-2.26332

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued

'

'

'

17,444,824

12,919,367

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

883,662

2,000,000

1,767,316

4,000,000

1,325,487

3,000,000

'

'

Common Stock, Value, Issued

'

'

'

$17,445

$12,919

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$12,000

'

$24,000

'

$18,000

'

'

'

Stock Issued During Period, Shares, Acquisitions

'

'

862,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

862,500

'

'

'

'

'

'

'

'

'

'

Equity Issuance, Per Share Amount

'

'

'

'

'

'

'

'

'

'

'

$5.80

'

'

'

'

'

'

'

'

$0.01

$0.01

$0.01

$0.01

$0.01

$0.01

'

$5.70

Sale of Stock, Number of Shares Issued in Transaction

'

'

'

'

'

'

'

'

'

'

'

'

5,256,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

$1.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

5,256,800

788,520

'

788,520

'

325,000

325,000

'

'

'

'

'

'

'

'

58,500

Proceeds from Issuance of Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

6,571,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash Fee Equals to Percentage of Gross Proceeds from Sale of Common Stock and Warrants

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of Non-Accountable Expense Allowance

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fees and Commissions, Other

'

'

'

'

'

'

'

'

'

'

857,230

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and Rights Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

228,712

'

267,164

'

'

'

'

'

'

'

'

'

1,808,025

'

Exercise Price of Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.25

'

$1.60

'

$5

'

'

'

'

'

'

'

'

'

'

Fair Value of Warrants (in dollars per warrant)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.29

'

$0.34

'

'

'

'

'

'

'

'

'

$0.34

'

Initial Fair Value of Warrants

'

'

'

'

'

'

'

'

'

'

495,876

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance

'

'

'

'

'

1,000,000

'

'

500,000

450,275

'

'

'

'

'

'

'

'

'

2,263,320

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

471,624

471,624

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures

'

'

'

'

'

'

'

5,546

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Adjustment of Warrants

'

'

'

'

'

'

'

'

'

'

'

$72,549

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

'

4,775,550

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total

'

'

'

'

'

'

122,740

857,394

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONCENTRATION_OF_CREDIT_RISK_D

CONCENTRATION OF CREDIT RISK (Details Textual) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Cash, FDIC Insured Amount	$250,000	'
Cash, Uninsured Amount	$7,443,561	$1,475,197

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Sep. 30, 2013
2014	$380,767
2015	62,451
2016	0
2017	0
2018	0
Thereafter	0
Total minimum lease payments	$443,218

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)

9 Months Ended

53 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2011

Sep. 29, 2010

Dec. 31, 2012

Mar. 04, 2011

Sep. 30, 2013

Jul. 31, 2013

Sep. 30, 2013

Dec. 09, 2011

Dec. 09, 2011

Dec. 09, 2011

Dec. 09, 2011

Affymetrix In [Member]

Robert Kelly [Member]

Lease Agreement 2010 [Member]

Lease Agreement 2010 [Member]

Lease Agreement March 2011 [Member]

Lease Agreement March 2011 [Member]

Lease Agreement July 2011 [Member]

Lease Agreement December 2011 [Member]

Lease Agreement December 2011 [Member]

Lease Agreement December 2011 [Member]

Lease Agreement December 2011 [Member]

Lease Agreement December 2011 [Member]

Ownership Program Agreement [Member]

Complegen Inc [Member]

Complegen Inc [Member]

Sanders Properties, Llc [Member]

Sanders Properties, Llc [Member]

ARE LLC [Member]

Fred Hutchinson Research Center [Member]

Fred Hutchinson Research Center [Member]

Fred Hutchinson Research Center [Member]

Fred Hutchinson Research Center [Member]

Fred Hutchinson Research Center [Member]

Monthly Rent For Period From February 24, 2012 To August 31, 2012 [Member]

Monthly Rent For Period From September 1, 2012 To August 31, 2013 [Member]

Monthly Rent For Period From September 1, 2013 To November 29, 2014 [Member]

Monthly Lease Rent

'

'

'

'

'

'

$3,658

'

$1,100

'

$4,800

'

'

$16,395

$19,923

$20,548

Security Deposit

36,446

'

36,446

36,447

'

'

3,658

'

1,500

'

'

'

32,789

'

'

'

Enhanced Lease Rent

'

'

'

'

'

'

'

4,267

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense

'

'

'

'

'

'

'

46,529

'

8,800

'

233,260

'

'

'

'

Lease Expiration Date, Description

'

'

'

'

'

'

'

'

'

'

'The lease is from August 2013 through November 2014

'

'

'

'

'

Loss Contingency, Damages Sought, Value

'

'

'

'

'

450,000

'

'

'

'

'

'

'

'

'

'

Payments for Software, Total

'

'

'

'

21,590

'

'

'

'

'

'

'

'

'

'

'

Purchase Obligation, Total

'

'

'

'

647,700

'

'

'

'

'

'

'

'

'

'

'

Contract Receivable, Due in Rolling Year Two

'

'

'

'

51,600

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Software

54,667

0

135,133

'

94,723

'

'

'

'

'

'

'

'

'

'

'

Loss Contingency, Accrual, Current

$402,840

'

$402,840

$0

'

'

'

'

'

'

'

'

'

'

'

'

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details) (USD $)

1 Months Ended

37 Months Ended

36 Months Ended

9 Months Ended

36 Months Ended

9 Months Ended

12 Months Ended

36 Months Ended

9 Months Ended

36 Months Ended

36 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Oct. 31, 2010

Jan. 31, 2010

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Feb. 29, 2012

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2011

Sep. 30, 2013

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees [Member]

Employees [Member]

Employees [Member]

Employees [Member]

Employees [Member]

Employees [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Dr.Hunkapiller [Member]

Dr.Hunkapiller [Member]

Stock Option One [Member]

Stock Option One [Member]

Stock Option Two [Member]

Stock Option Two [Member]

Stock Option One [Member]

Stock Option Two [Member]

Stock Option Two [Member]

Stock Option Two [Member]

Stock Option Two [Member]

Stock Option One [Member]

Stock Option One [Member]

Stock Option One [Member]

Stock Option Two [Member]

Stock Option Two [Member]

Stock Option Two [Member]

Stock Option One [Member]

Stock Option One [Member]

Stock Option One [Member]

Stock Option One [Member]

Stock Option Two [Member]

Stock Option Two [Member]

Stock Option Two [Member]

Stock Option One [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Date of grant

'

'

'

31-Jul-10

'

31-Mar-13

'

30-Sep-11

'

'

'

'

31-Dec-12

'

'

'

'

'

'

'

'

'

31-May-13

'

'

'

'

Date of grant start

'

'

'

'

'

'

'

'

31-Jan-13

'

'

'

'

'

'

31-Jan-13

'

'

30-Apr-12

'

'

'

'

'

'

'

'

Date of grant end

'

'

'

'

'

'

'

'

30-Jun-13

'

'

'

'

'

'

31-Aug-13

'

'

30-Sep-11

'

'

'

'

'

'

'

'

Fair value of common stock on date of grant

$2.76

$2.76

$3

$2.76

[1]

'

$6.57

[2]

'

$0.91

[3]

'

$4.11

[2]

$4.58

[2]

'

'

$4.11

[2]

$4.24

[2]

'

$3.95

[2]

$5.19

[2]

$0.91

[4]

'

'

'

$6.59

[2]

'

'

$0.91

$0.91

Exercise price of the options

'

'

'

$5

$5

$6.57

$7

$1.25

'

$4.11

$4.58

'

'

$4.11

$4.24

'

$3.95

$5.19

'

$6

$1.25

$6

$6

'

'

'

$1.25

Expected life of the options (years)

'

'

'

'3 years 3 months 29 days

'

'5 years

'

'5 years 7 months 24 days

'

'5 years

'6 years 1 month 10 days

'

'

'5 years 8 months 26 days

'6 years 1 month 10 days

'

'6 years 1 month 2 days

'6 years 1 month 10 days

'

'

'5 years

'5 years 7 months 24 days

'

'5 years

'5 years 3 months 22 days

'

'

Dividend yield

'

'

'

0.00%

'

0.00%

'

0.00%

0.00%

'

'

'

0.00%

'

'

0.00%

'

'

0.00%

'

'

'

0.00%

'

'

'

'

Expected volatility

'

'

'

58.59%

'

47.09%

'

53.90%

'

40.96%

41.05%

'

'

42.44%

44.58%

'

40.73%

40.92%

'

'

53.90%

62.46%

'

41.06%

41.09%

'

'

Risk-free interest rate

'

'

'

1.03%

'

1.13%

'

1.08%

'

1.03%

'

1.36%

'

0.91%

0.99%

'

1.73%

1.97%

'

'

0.89%

1.08%

'

0.73%

0.84%

'

'

Expected forfeiture per year (%)

'

'

'

0.00%

'

0.00%

'

10.00%

10.00%

'

'

'

10.00%

'

'

10.00%

'

'

0.00%

'

'

'

10.00%

'

'

'

'

Weighted-average fair value of the options (per unit)

'

'

'

0.6744

'

2.7

'

0.3579

'

1.69

1.89

'

'

1.7426

1.7842

'

1.35

2.18

'

'

0.3579

3.0367

'

2.41

2.49

'

'

[1]

The fair value of the Company's common stock was derived implicitly from the public offering filed in March 2010 at $3.00 per share and from the terms of an underwritten offering contemplated in July 2010 at $6.00 per Unit that was filed in October 2010, with $2.756 per share being allocated to common stock using an iterative approach in order for the combined fair value of the common stock and warrants to equal the amount of consideration to be received for the offering.

[2]

The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.

[3]

The fair value of the Company's common stock was derived implicitly from the Private Placement during April through June 2011 at $1.25 per Unit, wherein one Unit was comprised of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $1.60 per share.

[4]

The fair value of the Company's common stock was derived implicitly from the public offering filed in February 2012 at $6.00 per share.

RELATED_PARTY_TRANSACTIONS_Det1

RELATED PARTY TRANSACTIONS (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2013
Number of Underlying Shares, Outstanding as of January 1, 2013 (in shares)	1,052,137
Number of Underlying Shares, Granted (in shares)	1,425,394
Number of Underlying Shares, Expired (in shares)	-3,812
Number of Underlying Shares, Forfeited (in shares)	-221,522
Number of Underlying Shares, Exercised (in shares)	-5,546
Number of Underlying Shares, Outstanding as of September 30, 2013 (in shares)	2,246,651
Number of Underlying Shares, Exercisable as of September 30, 2013 (in shares)	1,044,549
Number of Underlying Shares, Vested and expected to vest (in shares)	2,090,475	[1]
Weighted-Average Exercise Price Per Share, Outstanding as of January 1, 2013 (in dollars per share)	$3.79
Weighted-Average Exercise Price Per Share, Granted (in dollars per share)	$5.02
Weighted-Average Exercise Price Per Share, Expired (in dollars per share)	$4.99
Weighted-Average Exercise Price Per Share, Forfeited (in dollars per share)	$4.21
Weighted-Average Exercise Price Per Share, Exercised (in dollars per share)	$1.79
Weighted-Average Exercise Price Per Share, Outstanding as of September 30, 2013 (in dollars per share)	$4.53
Weighted-Average Exercise Price Per Share, Exercisable as of September 30, 2013 (in dollars per share)	$4.54
Weighted-Average Exercise Price Per Share, Vested and expected to vest (in dollars per share)	$4.54	[1]
Weighted-Average Contractual Life Remaining in Years, Outstanding as of September 30, 2013	'8 years 10 months 13 days
Weighted-Average Contractual Life Remaining in Years, Exercisable as of September 30, 2013	'8 years 2 months 16 days
Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest	'8 years 9 months 29 days	[1]
[1]	vested shares and unvested shares after a forfeiture rate is applied.

RELATED_PARTY_TRANSACTIONS_Det2

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)

9 Months Ended

53 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

8 Months Ended

12 Months Ended

20 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

1 Months Ended

37 Months Ended

36 Months Ended

9 Months Ended

36 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

36 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Jun. 30, 2011

Feb. 29, 2012

Feb. 29, 2012

Jun. 30, 2010

Jun. 30, 2010

Dec. 31, 2009

Dec. 31, 2012

Dec. 31, 2009

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2011

Sep. 30, 2013

Dec. 31, 2011

Oct. 11, 2012

Jun. 30, 2012

Dec. 31, 2012

Jul. 30, 2012

Mar. 31, 2011

Nov. 03, 2010

Jun. 30, 2010

16-May-11

26-May-09

31-May-11

Mar. 31, 2011

Jun. 30, 2010

Dec. 31, 2010

19-May-11

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2010

Dec. 31, 2010

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2010

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2010

Dec. 31, 2010

Sep. 30, 2013

Sep. 30, 2012

Oct. 31, 2010

Jan. 31, 2010

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Feb. 29, 2012

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2011

Dec. 31, 2012

Investor Warrants [Member]

Minimum [Member]

Maximum [Member]

Ensisheim Partners Llc [Member]

Ensisheim Partners Llc [Member]

Ensisheim Partners Llc [Member]

Ensisheim Partners Llc [Member]

Ensisheim Partners Llc [Member]

Ensisheim Partners Llc [Member]

Robert L.Kelly [Member]

Dr.Hunkapiller [Member]

Dr.Hunkapiller [Member]

Dr.Hunkapiller [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Board Of Directors Chairman and Chief Executive Office [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Former President [Member]

Chief Scientific Officer [Member]

Chief Scientific Officer [Member]

Chief Scientific Officer [Member]

Chief Scientific Officer [Member]

Chief Scientific Officer [Member]

Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Non-Employee Director [Member]

Non-Employee Director [Member]

Non-Employee Director [Member]

Non-Employee Director [Member]

Non-Employee Director [Member]

Non-Employee Director [Member]

Non-Employee Director [Member]

Stock Option One [Member]

Stock Option and Incentive Plan 2010 [Member]

Promissory Note One [Member]

Promissory Note One [Member]

Promissory Note One [Member]

Promissory Note Two [Member]

Promissory Note Two [Member]

Promissory Note Two [Member]

Promissory Note Two [Member]

Promissory Note Two [Member]

Prior to Reverse Stock Split [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Prior to Reverse Stock Split [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Stock Option One [Member]

Stock Option One [Member]

Stock Option Two [Member]

Stock Option Two [Member]

Stock Option One [Member]

Stock Option Two [Member]

Stock Option Two [Member]

Stock Option and Incentive Plan 2010 [Member]

Non-Qualified Stock Options Were Granted Under The 2010 Plan [Member]

Non-Qualified Stock Options Were Granted Under The 2010 Plan [Member]

Non-Qualified Stock Options Were Granted Under The 2010 Plan [Member]

Non Qualified Stock Options Were Granted Outside Of 2010 Plan [Member]

Stock Option One [Member]

Stock Option One [Member]

Stock Option One [Member]

Stock Option One [Member]

Stock Option Two [Member]

Stock Option and Incentive Plan 2010 [Member]

Stock Option and Incentive Plan 2010 [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Stock Option One [Member]

Stock Option Two [Member]

Short-term Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Payable, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

439

'

'

'

'

'

8,959

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan Processing Fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

4,000

4,000

4,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Interest Rate During Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Current Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

79,300

'

140,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Accrued Interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,440

'

'

'

6,093

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Periodic Payment, Principal

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

79,300

5,078

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exclusive License Agreement, Royalty Percentage

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exclusive License Agreement, Minimum Royalty

'

'

'

'

'

'

'

'

'

'

'

12,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exclusive License Agreement, Minimum Royalty Increased

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patents Expenses

'

'

'

'

'

'

'

'

'

'

'

'

16,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty Income

'

'

'

'

'

'

'

12,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Lease Annual Rent

'

'

'

'

'

'

'

'

'

13,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense

'

'

'

'

'

'

'

'

6,600

248

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Security Deposit Related to Lease

'

'

'

'

'

'

'

'

'

1,100

'

1,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Security Deposit Refund

'

'

'

'

'

'

'

'

'

'

1,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual Base Salary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

360,000

'

'

'

350,000

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Salaries and Bonus

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

258,635

269,438

'

'

129,316

134,719

'

191,908

200,550

'

'

191,908

200,550

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Modified Annual Base Salary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,425,394

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

565,830

'

'

'

'

'

100,000

226,332

'

'

'

'

'

'

'

'

'

'

'

'

219,000

'

'

228,000

200,000

'

'

'

'

'

200,000

19,757

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'(i) 11,250 option shares shall vest ninety (90) days after the date of grant; (ii) 11,000 option shares shall vest one hundred and eighty (180) days after the date of grant; iii) 11,500 option shares shall vest two hundred and seventy (270) days after the date of grant; (iv) 11,250 option shares shall vest three hundred and sixty (360) days after the date of grant.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'25% (or 62,500 shares) vested on December 31, 2010 with the remaining 75% (or 187,500 shares) to vest in equal quarterly installments over the next three years so long as the executive remains employed with the company.

'

'

'

'

'

'

'25% (or 25,000 shares) vested on December 31, 2010 with the remaining 75% (or 75,000 shares) to vest in equal quarterly installments over the next three years so long as the executive remains employed with the company.

'

'

'

'

'

'

'

'

'

'

'

'

'

'(i) twenty-five percent (25%) of the underlying shares on the first anniversary of the date of grant; and (ii) forty eighth (1/48) of the underlying shares monthly thereafter.

'

'

'(i) twenty-five percent (25%) of the underlying shares on the first anniversary of the date employment commenced; and (ii) one-sixteenth (1/16) of the underlying shares quarterly thereafter.

'

'

'

'

'

'

'(i) 80,000 option shares shall vest on September 1, 2011; (ii) 30,000 options shares shall vest on December 1, 2011; (iii) 30,000 options shares shall vest on March 1, 2012; (iv) 30,000 options shares shall vest on June 1, 2012; (v) 30,000 options shares shall vest on September 1, 2012.

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

2,246,651

'

2,246,651

1,052,137

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

62,500

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding Number

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

187,500

'

'

'

'

'

'

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'10 years

'10 years

'

'

'

'

'

'10 years

'10 years

Share-based Compensation

1,187,717

96,251

1,479,981

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,187,716

96,251

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$5.02

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5

'

'

'

'

'

'

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.25

'

'

$4.24

$4.11

'

'

'

'

'

$1.25

$6

Offer Price Per Share

'

'

'

'

'

$5

$7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value

$3,604,669

'

$3,604,669

$1,150,416

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.91

$0.91

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.76

$2.76

$3

$2.76

[1]

'

$6.57

[2]

'

$0.91

[3]

$4.11

[2]

$4.58

[2]

'

'

'

'

'

$0.91

[4]

'

'

'

$6.59

[2]

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price

'

'

'

'

$1.60

'

'

'

'

'

'

'

'

'

'

$1.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5

$5

$6.57

$7

$1.25

$4.11

$4.58

'

'

'

'

'

'

$6

$1.25

$6

$6

'

'

[1]

The fair value of the Company's common stock was derived implicitly from the public offering filed in March 2010 at $3.00 per share and from the terms of an underwritten offering contemplated in July 2010 at $6.00 per Unit that was filed in October 2010, with $2.756 per share being allocated to common stock using an iterative approach in order for the combined fair value of the common stock and warrants to equal the amount of consideration to be received for the offering.

[2]

The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.

[3]

The fair value of the Company's common stock was derived implicitly from the Private Placement during April through June 2011 at $1.25 per Unit, wherein one Unit was comprised of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $1.60 per share.

[4]

The fair value of the Company's common stock was derived implicitly from the public offering filed in February 2012 at $6.00 per share.

ASSET_PURCHASE_Details_Textual

ASSET PURCHASE (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2012
Cash Acquired from Acquisition	$400,000
Stock Issued During Period, Shares, Acquisitions	862,500
Share Price	$5
Warrants Issued During Period Acquisitions	325,000
Warrants Exercise Price	$5
Warrant Terms	'5 years
Warrant Price	$2.35

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013
			Subsequent Event [Member]
			Aspire Capital Fund, Llc [Member]
Stock Issued During Period, Shares, New Issues	'	'	200,000
Stock Issued During Period, Value, New Issues	'	'	$349,670
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'	'	'30 months
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	'	'	8-Nov-13
Commitment From Investors To Purchase Of Common Stock	'	'	25,000,000
Loss Contingency, Accrual, Current	$402,840	$0	'